• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.

作者信息

Lora-Tamayo Jaime, Maestro Guillermo, Lalueza Antonio, Rubio-Rivas Manuel, Villarreal Paul Gracia, Arnalich Fernández Francisco, Beato Pérez José Luis, Vargas Núñez Juan Antonio, Llorente Barrio Mónica, Lumbreras Bermejo Carlos

机构信息

Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre "i+12 Institute", Madrid, Spain.

Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre "i+12 Institute", Madrid, Spain.

出版信息

J Infect. 2021 Jun;82(6):276-316. doi: 10.1016/j.jinf.2021.02.011. Epub 2021 Feb 11.

DOI:10.1016/j.jinf.2021.02.011
PMID:33582204
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7877892/
Abstract
摘要

相似文献

1
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.早期洛匹那韦/利托那韦不能降低COVID-19患者的死亡率：一项大型多中心研究的结果。
J Infect. 2021 Jun;82(6):276-316. doi: 10.1016/j.jinf.2021.02.011. Epub 2021 Feb 11.
2
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.COVID-19 门诊患者的早期抗病毒治疗（FLARE）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.
3
In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.在重症 COVID-19 患者中，加用洛匹那韦-利托那韦联合常规治疗未能改善 28 天死亡率。
Ann Intern Med. 2021 Jan;174(1):JC3. doi: 10.7326/ACPJ202101190-003. Epub 2021 Jan 5.
4
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?洛匹那韦/利托那韦在新冠病毒感染中的应用：是否完全无益？
J Microbiol Immunol Infect. 2020 Oct;53(5):674-675. doi: 10.1016/j.jmii.2020.05.014. Epub 2020 May 25.
5
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.洛匹那韦/利托那韦作为 SARS-CoV-2 感染抗病毒方案中的第三种药物。
J Chemother. 2021 May;33(3):193-197. doi: 10.1080/1120009X.2020.1775424. Epub 2020 Jun 12.
6
Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.阿比多尔与洛匹那韦/利托那韦治疗 2019 冠状病毒病的 Meta 分析。
J Med Virol. 2022 Apr;94(4):1513-1522. doi: 10.1002/jmv.27481. Epub 2021 Dec 6.
7
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.洛匹那韦/利托那韦联合疗法用于印度有症状的 2019 冠状病毒病患者：限制公共卫生紧急使用的方案。
Indian J Med Res. 2020;151(2 & 3):184-189. doi: 10.4103/ijmr.IJMR_502_20.
8
Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients.洛匹那韦/利托那韦在 COVID-19 患者中的血浆浓度与安全性。
Ther Drug Monit. 2021 Feb 1;43(1):131-135. doi: 10.1097/FTD.0000000000000838.
9
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.早期 COVID-19 治疗试验：与住院时间、死亡率和相关费用的关系。
Swiss Med Wkly. 2020 Dec 31;150:w20446. doi: 10.4414/smw.2020.20446. eCollection 2020 Dec 14.
10
Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.洛匹那韦利托那韦单独或联合利巴韦林治疗 73 例住院 COVID-19 患者：一项初步回顾性研究。
Int J Clin Pharmacol Ther. 2021 May;59(5):378-385. doi: 10.5414/CP203861.

引用本文的文献

1
A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity.用于评估冠状病毒 Nsp5/3CLpro 活性的海肾荧光素酶报告基因检测法。
Sci Rep. 2024 Sep 5;14(1):20697. doi: 10.1038/s41598-024-71305-6.
2
Variability of Steroid Prescription for COVID-19 Associated Pneumonia in Real-Life, Non-Trial Settings.现实生活中（非试验环境下）新冠病毒肺炎类固醇处方的变异性
J Crit Care Med (Targu Mures). 2022 Nov 12;8(4):259-265. doi: 10.2478/jccm-2022-0025. eCollection 2022 Oct.
3
WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales.世卫组织 COVID-19 等级量表和炎症风险类别。严重程度量表的比较研究。
J Gen Intern Med. 2022 Jun;37(8):1980-1987. doi: 10.1007/s11606-022-07511-7. Epub 2022 Apr 8.
4
The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.基于炎症标志物的 COVID-19 中皮质类固醇或托珠单抗的使用。
J Gen Intern Med. 2022 Jan;37(1):168-175. doi: 10.1007/s11606-021-07146-0. Epub 2021 Oct 18.
5
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.药物重新利用治疗新冠肺炎的疗效与安全性：2021年立场声明
Front Pharmacol. 2021 Jun 14;12:659577. doi: 10.3389/fphar.2021.659577. eCollection 2021.
6
High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?大剂量类固醇治疗重症新型冠状病毒肺炎：一种新的治疗手段？
Intern Emerg Med. 2021 Aug;16(5):1329-1330. doi: 10.1007/s11739-021-02722-y. Epub 2021 Apr 19.
7
Wuhan to World: The COVID-19 Pandemic.武汉走向世界：新冠疫情。
Front Cell Infect Microbiol. 2021 Mar 30;11:596201. doi: 10.3389/fcimb.2021.596201. eCollection 2021.

本文引用的文献

1
[Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry].[西班牙新冠肺炎住院患者的临床特征：SEMI-COVID-19登记研究结果]
Rev Clin Esp. 2020 Nov;220(8):480-494. doi: 10.1016/j.rce.2020.07.003. Epub 2020 Jul 19.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.2019冠状病毒病的潜在治疗选择：现状、挑战及未来展望
Front Pharmacol. 2020 Sep 15;11:572870. doi: 10.3389/fphar.2020.572870. eCollection 2020.
4
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.洛匹那韦利托那韦在因 COVID-19 住院的患者中的应用（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4. Epub 2020 Oct 5.
5
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.早期给予利托那韦增强型洛匹那韦可预防重症新型冠状病毒肺炎。
J Infect. 2021 Jan;82(1):159-198. doi: 10.1016/j.jinf.2020.05.039. Epub 2020 May 27.
6
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠病毒病的一项试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
7
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠肺炎的试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
8
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
9
How will country-based mitigation measures influence the course of the COVID-19 epidemic?基于国家的缓解措施将如何影响新冠疫情的发展进程？
Lancet. 2020 Mar 21;395(10228):931-934. doi: 10.1016/S0140-6736(20)30567-5. Epub 2020 Mar 9.